Effective Treatment for Lung Cancer with BRAF Mutation
Author Information
Author(s): Muacevic Alexander, Adler John R, Anai Satoshi, Isa Kohei, Chibana Rin, Ueno Shiho, Sato Yoko
Primary Institution: Yuuai Medical Center, Okinawa, JPN
Hypothesis
Can dabrafenib and trametinib be effective in a patient with BRAF V600E-mutated lung cancer and poor performance status?
Conclusion
The patient showed significant clinical and radiological improvements after treatment with dabrafenib and trametinib.
Supporting Evidence
- The patient had a BRAF V600E mutation confirmed by biopsy.
- After treatment, the patient no longer required supplemental oxygen.
- Imaging showed marked improvement of the pulmonary infiltrate after treatment.
Takeaway
A 73-year-old man with lung cancer got better after taking two medicines, even though he was very sick before.
Methodology
The patient was treated with dabrafenib and trametinib after confirming the BRAF V600E mutation through biopsy.
Limitations
This is a single case report, limiting the generalizability of the findings.
Participant Demographics
73-year-old male with a history of smoking and poor performance status.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website